Last reviewed · How we verify

Oncothyreon Canada Inc. — Portfolio Competitive Intelligence Brief

Oncothyreon Canada Inc. pipeline: 0 marketed, 0 filed, 1 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 1 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
THERATOPE STn-KLH vaccine THERATOPE STn-KLH vaccine phase 3 vaccine STn antigen Oncology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Aduro Biotech, Inc. · 1 shared drug class
  2. Aeras · 1 shared drug class
  3. Aga Khan University · 1 shared drug class
  4. Aimei Vacin BioPharm (Zhejiang) Co., Ltd. · 1 shared drug class
  5. Alba Maria Ropero · 1 shared drug class
  6. Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. · 1 shared drug class
  7. Asoc. Prof. Erdoğan Selçuk Şeber · 1 shared drug class
  8. ANRS, Emerging Infectious Diseases · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Oncothyreon Canada Inc.:

Cite this brief

Drug Landscape (2026). Oncothyreon Canada Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/oncothyreon-canada-inc. Accessed 2026-05-16.

Related